- Home
- GCV vs SCLX Comparison
GCV vs SCLX Comparison
Compare GCV & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCV
- SCLX
- Stock Information
- Founded
- GCV 1988
- SCLX 2011
- Country
- GCV United States
- SCLX United States
- Employees
- GCV N/A
- SCLX N/A
- Industry
- GCV Finance/Investors Services
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- GCV Finance
- SCLX Health Care
- Exchange
- GCV Nasdaq
- SCLX Nasdaq
- Market Cap
- GCV 75.6M
- SCLX 61.5M
- IPO Year
- GCV N/A
- SCLX N/A
- Fundamental
- Price
- GCV $3.95
- SCLX $0.33
- Analyst Decision
- GCV
- SCLX Strong Buy
- Analyst Count
- GCV 0
- SCLX 4
- Target Price
- GCV N/A
- SCLX $14.00
- AVG Volume (30 Days)
- GCV 57.9K
- SCLX 184.3K
- Earning Date
- GCV 01-01-0001
- SCLX 03-11-2025
- Dividend Yield
- GCV 13.04%
- SCLX N/A
- EPS Growth
- GCV N/A
- SCLX N/A
- EPS
- GCV N/A
- SCLX N/A
- Revenue
- GCV N/A
- SCLX $55,152,000.00
- Revenue This Year
- GCV N/A
- SCLX $24.19
- Revenue Next Year
- GCV N/A
- SCLX $109.90
- P/E Ratio
- GCV N/A
- SCLX N/A
- Revenue Growth
- GCV N/A
- SCLX 22.02
- 52 Week Low
- GCV $3.15
- SCLX $0.32
- 52 Week High
- GCV $4.58
- SCLX $2.63
- Technical
- Relative Strength Index (RSI)
- GCV 57.55
- SCLX 30.09
- Support Level
- GCV $3.86
- SCLX $0.33
- Resistance Level
- GCV $3.90
- SCLX $0.36
- Average True Range (ATR)
- GCV 0.05
- SCLX 0.03
- MACD
- GCV 0.01
- SCLX -0.00
- Stochastic Oscillator
- GCV 52.17
- SCLX 8.90
About GCV Gabelli Convertible and Income Securities Fund Inc. (The)
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.